Tag Archive for: Radiopharmaceutical

ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma

/in

Los Angeles, California, USA, December 6th, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy (RPT) products, today announces the start of a Phase II clinical trial at Hull University Teaching Hospitals NHS Trust in the UK. The trial, named PRETZCEL, will investigate ImaginAb’s […]

Read more

Radio what’s new? Tuning in to turning cancer cells off

/in

Tuning in to the field of targeted cancer medicine through molecular radiotherapy or targeted radionuclides.

Read more

Theragnostics strengthens leadership team with two key appointments

/in

Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical drug development expert Dr Daniel Stevens joins as Chief Medical Officer LONDON, UK, 14 November 2019 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces two strategic hires to its leadership team with the appointment of Dr Daniel Stevens […]

Read more